Fairvalue-Calculator Fairvalue-Calculator
EN DE

BioGaia AB (BGLAF) Fair Value & Analysis

Healthcare · US · Market cap $1.2B

Price$11.79
Fair Value$6.92
Upside-41.3%
Quality95/100
Evidence: High Range $4.93 – $8.66

Fair value as of: Jun 24, 2026

Analysis

BioGaia AB (BGLAF) currently trades at $11.79, while our model-based Fair Value estimate is $6.92 — implying the stock looks roughly 41.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. Its Adult Health segment provides gut health tablets, bone health tablets, and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment offers packaging solutions. It sells its products through distribution partners or through its own distribution channels. The company was incorporated in 1990 and is headquartered in Stockholm, Sweden.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

Frequently asked questions

Is BioGaia AB (BGLAF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $6.92 versus a price of $11.79 — about −41% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BGLAF?
Our 21-model fair value for BioGaia AB is $6.92 (as of Jun 24, 2026), built from audited fundamentals. The current price is $11.79.
What is the quality score of BGLAF?
BioGaia AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.